Výsledky vyhledávání - "R Y Gabriëls"

DOP15 Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy

Autor: R Y Gabriëls, M Linssen, A van der Waaij, P Volkmer, W Hooghiemstra, G Kats-Ugurlu, D Robinson, G Dijkstra, W Nagengast

Publikováno v: Journal of Crohn's and Colitis. 16:i064-i065

Background Vedolizumab is a monoclonal antibody which blocks integrin α4β7 inhibiting trafficking of T-lymphocytes into the gut. Unfortunately, up to 60% of vedolizumab patients experience non-response. The mechanism of action of vedolizumab is not

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d79c2d3f25f7f1552059c38e4269872f
https://doi.org/10.1093/ecco-jcc/jjab232.054

Zobrazit plný text záznamu

P577 Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease

Autor: R Y Gabriëls, A R Bourgonje, J von Martels, T Blokzijl, R Weersma, K Galinsky, J Julius, K N Faber, G Kats-Ugurlu, G Dijkstra

Publikováno v: Journal of Crohn's and Colitis. 16:i517-i518

Background Vedolizumab has shown efficacy, safety and tolerability as treatment for patients with inflammatory bowel disease (IBD). However, vedolizumab induction therapy only shows clinical response and remission in roughly 55% and 30% of IBD patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::582e4b092779db4c84c9d7f0ada0f69b
https://doi.org/10.1093/ecco-jcc/jjab232.703

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání